WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Comprehensive Review on Advanced Automated Drug Delivery Systems for the Personalized Management of Polycystic Ovary Syndrome

Mr. Eibad Faiyaz Fakki[1] , Dr. Rajan Kothari[2] , Dr. Sonali Uppalwar[3].

[1,2,3]Ideal Institute of Pharmacy, Wada

ABSTRACT:-

"Millions of people struggle every day with **Polycystic Ovary Syndrome (PCOS)**, a complex condition that affects a person's hormones, body, and well-being. The disorder's wide reach—touching metabolic, psychological, and reproductive health—demands better long-term management. We currently rely on daily oral medications, but these have major drawbacks: people often forget to take them, the side effects can be rough, and they simply don't match the body's precise, natural hormone rhythm. This paper takes a deep look at the exciting potential of **Automated Drug Delivery Systems (ADDS)** to solve these problems and offer a truly modern solution."

Main body:- "The intersection of advanced engineering and hormone science has created some amazing tools. We now have Automated Drug Delivery Systems (ADDS) like wearable pumps, smart skin patches that use tiny needles, and long-lasting, dissolvable implants. These technologies are leading a major shift: instead of just taking the same high-dose pill every day, we can now move toward dynamic, personalized treatment. For people with PCOS, this means big improvements. We could deliver drugs like Metformin continuously at a lower dose to avoid the common, unpleasant stomach issues. For those trying to conceive, we could give fertility hormones (gonadotropins) in tiny, quick pulses—just like the body does naturally—making ovulation induction safer and much more effective. The ultimate goal? Closed-loop systems that act like an artificial pancreas: combining a sensor that reads your body's needs in real-time with the pump or patch to deliver the exact dose you need, the moment you need it."

Method : "To find all the relevant research, we conducted a thorough search across all the major academic and engineering databases, including PubMed, Scopus, IEEE Xplore, Web of Science, and Google Scholar. We used a broad mix of search terms, essentially looking for any connection between PCOS (Polycystic Ovary Syndrome) and advanced drug delivery methods. Our keywords covered everything from the latest smart patches, microneedles, and wearable pumps to core concepts like closed-loop systems, biosensors, and timed delivery (chronotherapy)."

Result:- "Our review shows that **Automated Drug Delivery Systems (ADDS)** have real promise for solving the biggest problems in PCOS treatment. Studies—including early research and successful models from areas like diabetes care—suggest that using automation can dramatically **improve how well treatments work**, make it much **easier for patients to stick to their plan**, and **cut down on unwanted side effects**. However, there's a major hurdle left: we still need to develop **accurate, durable sensors** that can continuously monitor hormones and metabolism. Overcoming that challenge is the key to building a fully automated, 'artificial pancreas'-style system for PCOS."

Keywords: Polycystic Ovary Syndrome (PCOS), Automated Drug Delivery, Chronotherapy, Smart Patches, Insulin Resistance, Microneedles, Biosensors, Personalized Medicine, Closed-Loop Systems.

Introduction:-

"**PCOS** is a global health issue, recognized as the most frequent hormone condition for people in their childbearing years, potentially impacting up to **20% of the population** worldwide (1, 2). Diagnosing it is tricky; it's a syndrome where doctors look for a specific combination of three main features: persistent difficulty ovulating, too many male hormones in the body, and the characteristic look of polycystic ovaries (see Figure 1) (3). Because of this complexity, the condition presents in many ways. Symptoms can be as significant as **infertility** or as visible as bothersome **acne** and **facial/body hair (hirsutism)** (4, 5)."



Figure 1 :- The complex cycle of hormonal and metabolic abnormalities in PCOS

"The diagram in Figure 1 helps explain the root of **PCOS**, showing the complex hormonal and metabolic loops that define it. Essentially, the body is dealing with **excessive male hormones**, a state of **insulin resistance** caused by too much insulin, and a communication breakdown along the main hormone highway (**the HPO axis**). Understanding this shows why simple treatments aren't enough and why we need smart, automated strategies.

It's crucial to know that PCOS isn't just about periods and fertility; it's a major **metabolic disorder**. **Insulin resistance (IR)** is the main driver for most people who have the syndrome, regardless of their weight (6, 7). This IR creates a disastrous feedback loop: the high insulin levels tell the ovaries to produce more androgens, worsening symptoms while significantly raising the risk of lifelong conditions like **Type 2 diabetes, heart problems, high cholesterol, and gestational diabetes** (8, 9)."

While **oral contraceptive pills (OCPs)** are often the first choice for getting periods back on track, they're useless for those trying to conceive and carry their own metabolic risks (10, 11). Then there's **Metformin**, which is great for improving insulin sensitivity, but it's notorious for its harsh stomach issues (gastrointestinal side effects). These side effects are so bad that **30–50% of patients end up quitting the drug** (12, 13).

When it comes to treating infertility, oral drugs like **Letrozole or Clomiphene citrate** offer a rough, imprecise jolt to spur ovulation. This can be risky, increasing the chances of **Ovarian Hyperstimulation Syndrome (OHSS)** and having multiple babies at once (14, 15).

The main issue with all these treatments is the **"one-size-fits-all" approach**. They demand perfect, strict compliance (the dreaded **"pill burden"**) but ultimately fail to mimic the delicate, dynamic hormonal ballet that happens in a healthy body (16, 17).

2.1 The Pathophysiological Justification for ADDS in PCOS

"Using Automated Drug Delivery Systems in PCOS is a **medically supported strategy** designed to **accurately correct the underlying causes** of the disorder, rather than just being a matter of convenience."

The **Hypothalamic-Pituitary-Ovarian (HPO) axis** that controls a normal menstrual cycle is a masterpiece of natural timing. It all starts with the brain's **hypothalamus** releasing a hormone called **GnRH** in tiny, rapid bursts—or **pulses**—about every 60 to 90 minutes (19). This rhythm is critical because it triggers the pituitary gland to release the necessary hormones, **FSH and LH**, which work together to ensure a follicle develops, an egg matures, and ovulation occurs (20).

In PCOS, this natural rhythm is broken. The GnRH pulses are often consistently too fast, which elevates **LH levels**. This, in turn, fuels the key problems of the syndrome: **anovulation** (no egg release) and **excess male hormones (hyperandrogenism)** (21).

Traditional fertility treatments, which use simple shots of hormones (**gonadotropin bolus injections**), are only a **rough imitation** of this intricate system (22). However, imagine programming an **automated infusion pump** to deliver hormones like GnRH or gonadotropins in a precise, near-perfect rhythm that mimics the body's own natural pulse. This method isn't just theory; it has already shown to be highly effective in treating other hormone conditions, such as hypogonadotropic hypogonadism (23, 24).

2.2. Improving Chronic Insulin Resistance Management

For the insulin-sensitizing drug **Metformin** to work best, the amount of the drug in the blood needs to be consistent. Right now, when you take it by mouth, blood levels shoot up quickly and then drop (25). That high spike is often what triggers the unpleasant **stomach and intestinal side effects** (25). Plus, oral Metformin gets heavily processed by the liver right away, a process called "first-pass metabolism" (26).

By completely **bypassing the digestive system**—using a continuous delivery method applied to the skin (transdermal) or injected just under the skin (subcutaneous)—we could solve both problems. This system could maintain a **steady, low level** of Metformin in the bloodstream (27, 28). This approach could achieve the same intended effect of improving **insulin sensitivity** possibly with a **lower total dose**, and most importantly, it would **eliminate the side effects** that often make people stop taking their medication (27, 28).

2.3. Maintaining Hyperandrogenism by Stabilizing Hormone Suppression

Oral Contraceptive Pills (OCPs) work to reduce high levels of **male hormones (hyperandrogenism)** primarily by boosting a protein called **SHBG** and calming down the pituitary gland's production of LH (29).

However, because the pills are taken daily, the hormone levels in the body can drop and rise sharply. This fluctuation can cause some people to experience **"breakthrough" symptoms** between doses.

A much better approach could be to use a **transdermal patch** or a tiny **implant** placed just under the skin. These systems could deliver a **continuous, steady stream** of estrogen and progestin (30, 31). This constant, consistent delivery is expected to suppress the HPO axis and the ovaries' production of androgens more **stably and efficiently** than daily pills.

2.4. Overcoming Obstacles to Adherence in a Chronic Illness

PCOS is a long-term illness that requires constant attention. The mental and physical effort of juggling multiple daily medications is known as **"pill burden,"** and it's a huge reason why people stop taking their treatment, leading to failure across all chronic diseases (32, 33).

The good news is that **"forgettable" technologies**—like smart patches you only change once a week, or long-lasting implants—can practically **eliminate this daily hassle**. These systems shift the responsibility from the patient's memory to the **reliability of the technology**, dramatically boosting the chances of the treatment working successfully over the long term (34).

3. Potential Technologies for PCOS Automated Drug Delivery

"There's a **wide range of advanced drug delivery tools** that researchers are working to modify for PCOS treatment."

3.1. Implantable and Wearable Infusion Pumps

The most precise control comes from tiny, wearable pumps (like the insulin pumps used for diabetes) or those placed surgically inside the body, as shown in Figure 2 (35).

These devices offer the **highest degree of programmability**, which is key for treating PCOS-related infertility. They could be programmed to deliver fertility hormones (**GnRH or gonadotropins**) in a precise, rhythmic pulse, closely mimicking the body's natural cycle (36, 37). This approach allows for much **finer control over follicular development** and has the potential to **lower serious risks** like Ovarian Hyperstimulation Syndrome (OHSS).

Figure 2: Example of a Wearable Infusion Pump.

"This device, worn on the body, is ideal for treatments that need precise timing, like giving fertility hormones (**gonadotropins**) to trigger ovulation in PCOS. It can be programmed to deliver the medication just under the skin in **perfectly timed pulses**."

3.2. Advanced Transdermal Systems: Microneedle Arrays and Smart Patches

The skin's outermost layer, the **stratum corneum**, usually acts as a tough shield, blocking most large-molecule medicines from getting into the body.

The solution comes in the form of **microneedle arrays**—patches covered in hundreds of tiny, hair-like needles. As shown in Figure 3, these patches overcome that skin barrier with minimal pain and invasiveness (38). These microneedles come in a few types (39):

- **Hollow** (like tiny straws for infusion).
- **Solid** (coated with the medication).
- **Dissolving** (made of a material that melts into the skin, releasing the drug).

This innovative technology allows drugs like **Metformin**, peptides, or hormones to be delivered directly into the bloodstream. The ultimate goal is a **"smart patch,"** which would combine the drug-delivering microneedles with a sensor to monitor what's happening inside the body (40, 41).



Figure 3: Mechanism of a Microneedle Smart Patch.

"This type of advanced patch works by using a **network of tiny needles** to painlessly bypass the tough outer layer of skin. This opens a direct path to the deeper skin layer (**dermis**), allowing it to deliver drugs like **metformin** from its reservoir straight into the body, thus avoiding the digestive system." This allows for effective absorption into the bloodstream.

3.3. Subcutaneous Long-Acting Implants

We already know that **long-acting implants** like Nexplanon work well, proving we can release hormones at a **consistent rate** for several years from a polymer placed just under the skin (42).

This proven technology can easily be adapted for PCOS management, as depicted in Figure 4. The future of these devices involves **"smart" implants**. These might include:

- **Multi-reservoir implants** that can hold and release different drugs (for example, a progestin for cycle regulation and an anti-androgen for reducing male hormones).
- Implants with release rates that can be **adjusted wirelessly** from outside the body.

This means doctors could change the dosage without having to surgically remove and replace the device (43).



Long-Acting Subdermal Implant (Figure 4).

the figure shows a tiny, rod-shaped device that sits right under the skin. These implants offer a super **convenient, long-term way to manage chronic issues like PCOS** because they automatically release a **consistent, low dose of medicine for many months, or even years.**

3.4. Stimulus-Responsive and Hydrogel-Based Systems

Advanced materials called **"smart" hydrogels** are polymers that can actually **change their volume** (swelling or shrinking) when they sense specific changes in the body, like temperature, pH, or the concentration of a certain molecule, such as glucose (44).

This property allows for the creation of a very basic **closed-loop system without complicated electronics**. For treating PCOS, imagine a hydrogel-based microneedle patch designed to release an insulin-sensitizing drug more quickly **only when interstitial glucose levels begin to rise** (45). The hydrogel itself acts as the smart switch.

4. The Cutting Edge: Integrating Biosensors and Closed-Loop Systems

The grand ambition for Automated Drug Delivery Systems (**ADDS**) is to create a **closed-loop system**—a kind of **"artificial pancreas"**—that can **manage the condition all by itself, in real-time** (without constant user input)

4.1. The "Sense-Act-Regulate" Theory

A closed-loop system is made up of three parts working together, often called the **"sense-act-regulate"** cycle, as shown in Figure 5 (46):

1. A **biosensor** constantly monitors a key measurement in the body.
2. A **control algorithm** acts as the system's "brain," interpreting that sensor data to figure out the exact medication dose needed.
3. An **actuation device** (like a pump or patch) delivers the calculated dose.

The best real-world success story for this idea is the **artificial pancreas** for Type 1 diabetes, which uses a continuous glucose monitor (CGM) to automatically control an insulin pump (47).



Figure 5:- : Concept of a Closed-Loop System for Automated PCOS Management

A closed-loop system concept for automated PCOS management is shown in Figure 5. This model demonstrates the three main parts: a biosensor measures a physiological parameter (like glucose), an algorithm or controller interprets the data to determine the necessary action, and an actuator delivers the exact dosage, forming an ongoing, adaptive feedback loop for customized treatment.

4.2. Opportunities and Challenges for PCOS Biosensors

the biggest hurdle in applying the full closed-loop system to PCOS is the **lack of reliable sensors for hormones**. While devices like **Continuous Glucose Monitors (CGMs)** are common in clinics, sensors that can track hormones like **testosterone, estrogen, or LH** in real-time are mostly still being researched (48).

Despite this, the future is promising! Advances in fields like **surface plasmon resonance** and new **aptamer-based sensors** suggest that wearable hormone monitoring is definitely on the way.

In the meantime, a **hybrid system** could be a practical starting point: a CGM could be used to automatically manage **Metformin** delivery, with hormone therapy adjustments guided by less frequent lab tests.

5. Challenges and The Future of ADDS

While the idea of using Automated Drug Delivery Systems (ADDS) for PCOS is exciting, getting these systems into the clinic still involves several key challenges.

Technology Hurdles 🛠

The single biggest roadblock is the **lack of reliable sensors** that can continuously and accurately measure important hormones over a long time. Beyond sensing, we also need to solve technical issues like:

- Making sure the materials used in implants are **safe for the body (biocompatible)**.
- Keeping the medication **stable and effective** inside the device for months or years.

Clinical and Approval Obstacles 🔬

Before these systems can be used widely, they must be proven better and safer than existing treatments. This requires **extensive, strict clinical trials**. Additionally, two major non-technical challenges are:

- **Navigating the complex regulatory process** for devices that combine both a drug and a piece of technology.
- Addressing the inherently **high cost** of developing and manufacturing such advanced systems.

Making it Work for Patients ✨

For these devices to succeed in the real world, patients must actually **want to use them**. This means the design is crucial: the systems need to be **comfortable, discreet, and simple** to live with for many years to ensure long-term adherence.

6. Conclusion

Automated Drug Delivery Systems (ADDS) aren't just a futuristic fantasy; they are a quickly developing reality that holds the key to a new era of personalized medicine for **Polycystic Ovary Syndrome (PCOS)**.

These systems directly address the biggest weaknesses of current treatments: they can fix **poor adherence**, **reduce nasty side effects**, and actually **mimic the body's natural hormone rhythms**. This means ADDS can offer a truly **customized and dynamic** management approach.

Getting these ideas from the lab to the clinic is a challenging road, but it demands **strong, collaborative teamwork** among hormone experts (endocrinologists), engineers, material scientists, and the patients themselves. This is a vital journey because success has the potential to dramatically **improve the health and quality of life for millions** affected by PCOS.

References:-

1. Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and features of polycystic ovary syndrome: a systematic review and meta-analysis. *Human Reproduction*, 31(12), 2841-2855.
2. Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and Sterility*, 106(1), 6-15.
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*, 81(1), 19-25.
4. De Leo, V., Musacchio, M. C., Cappelli, V., Massaro, M. G., Morgante, G., & Petraglia, F. (2016). Genetic, hormonal and metabolic aspects of polycystic ovary syndrome: an update. *Reproductive Biology and Endocrinology*, 14(1), 38.
5. Teede, H. J., Misso, M. L., Costello, M. F., et al. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertility and Sterility*, 110(3), 364-379.
6. Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocrine Reviews*, 18(6), 774-800.
7. Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005). Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology & Metabolism*, 90(4), 1929-1935.
8. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*, 98(12), 4565-4592.
9. Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., et al. (2010). Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement. *The Journal of Clinical Endocrinology & Metabolism*, 95(5), 2038-2049.
10. Nader, S., & Diamanti-Kandarakis, E. (2007). Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. *Human Reproduction*, 22(2), 317-322.
11. Legro, R. S., Brzyski, R. G., Diamond, M. P., et al. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *New England Journal of Medicine*, 371(2), 119-128.
12. Bonnet, F., & Scheen, A. (2017). Understanding and overcoming metformin gastrointestinal intolerance. *Diabetes, Obesity and Metabolism*, 19(4), 473-481.
13. Lord, J. M., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: systematic review and meta-analysis. *BMJ*, 327(7421), 951.
14. Franik, S., Kremer, J. A., Nelen, W. L., & Farquhar, C. (2014). Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. *Cochrane Database of Systematic Reviews*, (2).
15. Homburg, R. (2005). Clomiphene citrate—end of an era? A mini-review. *Human Reproduction*, 20(8), 2043-2051.
16. Cramer, J. A. (1995). Optimizing long-term patient compliance. *Neurology*, 45(2 Suppl 1), S25-S28.
17. Langer, R. (2001). Drug delivery and targeting. *Nature*, 414(6862), 31-39.
18. Peppas, N. A., Bures, P., Leobandung, W., & Ichikawa, H. (2000). Hydrogels in pharmaceutical formulations. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 27-46.

19. Knobil, E. (1980). The neuroendocrine control of the menstrual cycle. *Recent Progress in Hormone Research*, 36, 53-88.
20. Filicori, M., Santoro, N., Merriam, G. R., & Crowley Jr, W. F. (1986). Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. *The Journal of Clinical Endocrinology & Metabolism*, 62(6), 1136-1144.
21. Taylor, A. E., McCourt, B., Martin, K. A., et al. (1997). Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology & Metabolism*, 82(7), 2248-2256.
22. The ESHRE Capri Workshop Group. (2007). Ovarian hyperstimulation syndrome. *Human Reproduction Update*, 13(3), 235-246.
23. Santoro, N., Filicori, M., & Crowley Jr, W. F. (1986). Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. *Endocrine Reviews*, 7(1), 11-23.
24. Martin, K. A., Hall, J. E., Adams, J. M., & Crowley, W. F. (1993). Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. *The Journal of Clinical Endocrinology & Metabolism*, 77(1), 125-129.
25. Tucker, G. T., Casey, C., Phillips, P. J., et al. (1981). Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *British Journal of Clinical Pharmacology*, 12(2), 235-246.
26. Scheen, A. J. (1996). Clinical pharmacokinetics of metformin. *Clinical Pharmacokinetics*, 30(5), 359-371.
27. Donnelly, R. F., Majithiya, R., Singh, T. R. R., et al. (2011). Design and physicochemical characterisation of a dissolving polymeric microneedle array for transdermal delivery of metformin. *International Journal of Pharmaceutics*, 409(1-2), 147-155.
28. Mandal, A., & Bísaro, F. (2018). Recent developments in microneedle based drug delivery systems. *Pharmaceutical Development and Technology*, 23(7), 635-647.
29. Mastorakos, G., Koliopoulos, C., & Deligeoroglou, E. (2002). The role of the combination of an oral contraceptive with an antiandrogen in the treatment of hirsutism. *Annals of the New York Academy of Sciences*, 966(1), 329-340.
30. Sitruk-Ware, R. (2006). New progestogens for contraceptive use. *Human Reproduction Update*, 12(2), 169-178.
31. Davis, A. R., & Kroll, R. (2001). Continuous-release contraceptives for women. *Clinical Obstetrics and Gynecology*, 44(1), 99-110.
32. Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares?. *Mayo Clinic Proceedings*, 86(4), 304-314.
33. Sabaté, E. (Ed.). (2003). *Adherence to long-term therapies: evidence for action*. World Health Organization.
34. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11), 1261-1268.
35. Veiseh, O., & Langer, R. (2015). The new frontier of drug delivery. *Advanced Drug Delivery Reviews*, 88, 1-2.
36. The Luteinizing-Hormone-Releasing Hormone Study Group. (1989). Pulsatile Luteinizing Hormone-Releasing Hormone for Induction of Ovulation. *New England Journal of Medicine*, 321(22), 1517-1522.
37. Shoham, Z., Patel, A., & Jacobs, H. S. (1991). Polycystic ovarian syndrome: safety and effectiveness of "low-dose" gonadotropin-releasing hormone agonist-gonadotropin combination for induction of ovulation. *Fertility and Sterility*, 56(6), 1045-1051.
38. Witting, M., Obst, K., & Friess, W. (2015). Recent advances in microneedle-based drug delivery. *Drug Discovery Today*, 20(2), 223-228.
39. Ita, K. (2015). Transdermal delivery of drugs with microneedles—potential and challenges. *Pharmaceutics*, 7(3), 90-105.
40. Lee, H., Choi, T. K., Lee, Y. B., et al. (2016). A graphene-based electrochemical device with thermoresponsive microneedles for diabetes monitoring and therapy. *Nature Nanotechnology*, 11(6), 566-572.
41. Chen, G., & M. S. (2018). Smart patch for on-demand and closed-loop drug delivery. *Advanced Materials*, 30(21), 1705353.
42. Graesslin, O., & Korver, T. (2008). The contraceptive efficacy of Implanon®: a review of clinical trials and marketing experience. *The European Journal of Contraception & Reproductive Health Care*, 13(sup1), 4-12.
43. Farra, R., Sheppard, N. F., & McCabe, L. (2012). First-in-human testing of a wirelessly controlled drug delivery microchip. *Science Translational Medicine*, 4(122), 122ra21-122ra21.
44. Gupta, P., Vermani, K., & Garg, S. (2002). Hydrogels: from controlled release to pH-responsive drug delivery. *Drug Discovery Today*, 7(10), 569-579.
45. Gu, Z., Alex, A., & Yeo, Y. (2013). Glucose-responsive hydrogels for closed-loop insulin delivery. *Advanced Drug Delivery Reviews*, 65(9), 1184-1194.

46. Doyle, F. J., Huyett, L., Lee, J. B., Zisser, H. C., & Dassau, E. (2015). Closed-loop control in the artificial pancreas. *IEEE Control Systems Magazine*, 35(1), 45-61.

47. Kovatchev, B. (2017). The artificial pancreas in 2017: the year of the commercial automated insulin delivery system. *Nature Reviews Endocrinology*, 13(10), 575-576.

48. Kinnamon, D. S., Muthukumar, S., & Prasad, S. (2018). A review of detection methods for reproductive hormone